Six times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.
Neurimmune appoints John Dellapa
AppointmentsNeurimmune today announced the appointment of John Dellapa as General Counsel. John joins Neurimmune from the Boston office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, an AmLaw 100 law firm.
Genfit set to raise $100m in Nasdaq IPO
Latest NewsFrench Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.
Over 800 Participants from 40 Countries in 2,000 Meetings
Sponsored PublicationsSix times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.
Targeting NFkappaB protects tendons from injury
Latest NewsResearchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.
Anaveon bags CHF35m series A financing
Latest NewsUniversity Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.
AMR network CARB-X expands reach
Latest NewsThe global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR).
Roche swallows Spark Therapeutics in $4.3bn deal
Latest NewsSwiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.
How salt triggers allergy
Latest NewsSodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.
Calypso Biotech cash in €20M Series A financing
Latest NewsDutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the company’s seed investor M Ventures.
Evotec and HZI join forces in antibiotics discovery
Latest NewsEvotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.